Control elements of the tetracyclineresistance operon encoded in TnlO ofEscherichia coli have been utilized to establish a highly efficient regulatory system in mammalian cells. By fusing the tet repressor with the activating domain of virion protein 16 of herpes simplex virus, a tetracycline-controlled transactivator (tTA) was generated that is constitutively expressed in HeLa cells. This transactivator stimulates transcription from a minimal promoter sequence derived from the human cytomegalovirus promoter IE combined with tet operator sequences. Upon integration of a luciferase gene controlled by a tTA-dependent promoter into a tTA-producing HeLa cell line, high levels of luciferase expression were monitored. These activities are sensitive to tetracycline. Depending on the concentration of the antibiotic in the culture medium (0-1 pzg/ml), the luciferase activity can be regulated over up to five orders of magnitude. Thus, the system not only allows differential control of the activity of an individual gene in mammalian cells but also is suitable for creation of "on/off" situations for such genes in a reversible way. Here we describe a control system that in HeLa cells allows regulation of expression of an individual gene over up to five orders of magnitude. This system is based on regulatory elements of the TnlO-specified tetracycline-resistance operon of E. coli (19), in which transcription of resistancemediating genes is negatively regulated by the tetracycline repressor (tetR). In the presence of the antibiotic tetracycline tetR does not bind to its operators located within the promoter region of the operon and allows transcription. By combining tetR with the C-terminal domain of VP16 from HSV, known to be essential for the transcription of the immediate early viral genes (20), a hybrid transactivator was generated that stimulates minimal promoters fused to tetracycline operator (tetO) sequences. These promoters are virtually silent in the presence of low concentrations of tetracycline, which prevents the tetracycline-controlled transactivator (tTA) from binding to tetO sequences.
constitutively expressed in HeLa cells. This transactivator stimulates transcription from a minimal promoter sequence derived from the human cytomegalovirus promoter IE combined with tet operator sequences. Upon integration of a luciferase gene controlled by a tTA-dependent promoter into a tTA-producing HeLa cell line, high levels of luciferase expression were monitored. These activities are sensitive to tetracycline. Depending on the concentration of the antibiotic in the culture medium (0-1 pzg/ml), the luciferase activity can be regulated over up to five orders of magnitude. Thus, the system not only allows differential control of the activity of an individual gene in mammalian cells but also is suitable for creation of "on/off" situations for such genes in a reversible way.
The study of gene function in complex genetic environments such as mammalian cells would greatly profit from systems that would allow stringent control of the expression of individual genes. Ideally, such systems would not only mediate an "on/off" situation of gene activity but also would permit limited expression at a defined level.
Attempts to control gene activity by various inducible eukaryotic promoters responsive to, for example, heavy metal ions (1) (2) (3) , heat shock (4), or hormones (5) (6) (7) (8) have generally suffered from leakiness of the inactive state (e.g., the metallothionein promoter; ref. 1) or from pleiotropic effects caused by the inducing principles themselves, such as elevated temperature or glucocorticoid hormone action (9) .
In search of regulatory systems that do not rely on endogenous control elements, several groups, including ours, have demonstrated that the lac repressor/operator/inducer system of Escherichia coli functions in mammalian cells. Three basically different approaches have been described: (i) prevention of transcription initiation by properly placed lac operators at promoter sites (10) (11) (12) (13) (14) , (ii) blockage of transcribing RNA polymerase II during elongation by a lac repressor/operator complex (lacR/O; ref. 15) , and (iii) activation of a promoter responsive to a fusion between lacR and the activating domain of virion protein 16 (VP16) of herpes simplex virus (HSV) (16, 17) .
At present, however, the utility of the lacR/O-based systems in mammalian cells is limited since the inducer isopropyl /B-D-thiogalactopyranoside (IPTG), despite its rapid uptake and intracellular stability (18) , acts rather slowly and inefficiently, resulting in only moderate induction. Nevertheless, an interesting conditional mutant of a lacR-VP16 fusion has been described (17) . It activates a minimal promoter -'1000-fold at elevated temperatures in the presence of IPTG. The temperature dependence and the inherent IPTGrelated problems, however, may once again limit this approach.
Here we describe a control system that in HeLa cells allows regulation of expression of an individual gene over up to five orders of magnitude. This system is based on regulatory elements of the TnlO-specified tetracycline-resistance operon of E. coli (19) , in which transcription of resistancemediating genes is negatively regulated by the tetracycline repressor (tetR). In the presence of the antibiotic tetracycline tetR does not bind to its operators located within the promoter region of the operon and allows transcription. By combining tetR with the C-terminal domain of VP16 from HSV, known to be essential for the transcription of the immediate early viral genes (20) , a hybrid transactivator was generated that stimulates minimal promoters fused to tetracycline operator (tetO) sequences. These promoters are virtually silent in the presence of low concentrations of tetracycline, which prevents the tetracycline-controlled transactivator (tTA) from binding to tetO sequences.
The specificity of the tetR for its operator sequence (19) as well as the high affinity of tetracycline for tetR (21) and the well-studied chemical and physiological properties of tetracyclines constitute a basis for an inducible expression system in mammalian cells far superior to the 1acR/O/IPTG system. This has already been demonstrated in plant cells, in which direct repressor action at promoter sites is efficiently reversed by the antibiotic (22, 23) .
MATERIALS AND METHODS
Construction of the Transactivators tTA and tTAS. The tetR sequence was originally recovered from pWH510 (24) by PCR and inserted into pUHD10-1 (14) , resulting in pUHD14-1 (A. Bonin and H.B., unpublished). A unique Aft II cleavage site overlapping the tetR stop codon in this plasmid construct allows for the in-frame insertion of coding sequences. To generate tTA, a 397-base-pair (bp) Mlu IlFok I fragment of pMSVP16 (20) coding for the C-terminal 130 amino acids of VP16 of HSV was blunted by filling in the protruding ends with T4 DNA polymerase. This DNA was inserted into pUHD14-1 previously cleaved with Afl II and blunted by mung bean nuclease. The resulting plasmid pUHD15-1 encodes the tTA sequence (Fig. la) (25) . This promoter is lysates was determined according to Bradford (29) .
followed by a polylinker and the luciferase gene of Photinus pyralis fused to the SV40 small-t intron and poly(A) signal.
RESULTS
The latter elements and the luciferase gene were transferred from pSV2L-AA5' (26) . By this transfer the N terminus of Construction and Characterization of the tTA. To convert luciferase has been modified as described (14) . The enhancer the prokaryotic tet repressor into a eukaryotic transactivator region of PhcMv was removed by PCR-mediated cloning, it was fused to the negatively charged C-terminal domain of whereby a Xho I site was introduced adjacent to position HSV-VP16, known to be essential for transactivation (20) .
-53. The resulting minimal promoter, PhcMv* (Fig. lb) (Fig. lb) . tetO sequences were fused to this core promoter by insertions at the Xho I site (Fig. 1) .
The tetO sequence 02 ofTnlO is a 19-bp inverted repeat to which tetR binds as a 46-kDa dimer (19) . It was chemically synthesized and ligated into the Xho I cleavage site of the polylinker located upstream of the minimal tk promoter in plasmid pT81-luc (27 Quantitation of PhCMv*-1 and PhCMV*-2 Activation by tTA.
To quantify the stimulation of PhcMv*-tetO constructs by tTA, HeLa cell lines were established that contained the PhcMv*-1-or the PhcMv*-2-luciferase as well as the PhCMVtTA expression units stably integrated. Conditions for culturing and selecting cells have been described (14) . In a first step cells were cotransfected with pUHD15-1 and pSV2neo (30) . Clones resistant to G418 were assayed for transactivation ofPhcMv*-1 by transient transfection with pUHC13-3. In all HeLa. cell clones in which the tetracycline-responsive promoters were active, tTA was not detectable by Western blots or by immunofluorescence. Its presence was just barely visible in electrophoretic mobility shift experiments of highly labeled tetO DNA. This indicates very low intracellular concentrations of tTA and may reflect a selection against squelching effects caused by higher concentrations of VP16-activating domains (31) .
One of the positive clones, HtTA-1, was then cotransfected with a plasmid carrying the hygromycin-resistance gene (pHMR272; ref. 32 ) and either pUHC13-3 or pUHC13-4, resulting in the X and T series of clones, respectively. Clones resistant to hygromycin and G418 were assayed for luciferase activity. As shown in Table 1 , in the absence of tetracycline this activity differed in individual clones by almost four orders of magnitude. However, in all cases the luciferase activity was sensitive to tetracycline in the culture. This demonstrates that the expression of luciferase is dependent on the function of tTA, which obviously is capable of activating promoter constructs PhcMv*-1 and PhcMv*-2. (Table 1) tetracycline reduced luciferase activity to values that cannot be quantified even at high protein concentrations of the extracts due to instrumental limitations (i.e., rlu/,ug of protein c2). This demonstrates that PhCMv*-1 and PhCMv*-2 are virtually silent when integrated in the proper genomic environment and that their activity depends exclusively on the action of tTA.
The tTA inactivation studies were carried out with 1 ,ug of tetracycline per ml in the culture medium. A partial inactivation of tTA is, however, readily achieved with tetracycline concentrations below 0.1 ,g/ml, as shown in Fig. 3a . In the FIG. 3 . Dependence of tTA function on tetracycline. (a) Dependence of luciferase (luc.) activity on tetracycline concentration. HeLa cell clones X1 (dashed line) and T12 previously grown in tetracycline-free medium were seeded with a density of5000 cells per 35-mm dish and incubated at the tetracycline concentrations indicated. After reaching -90%o confluency, cells were harvested and assayed for luciferase activity. Data given are the means ± SD of three independent experiments. (b) Kinetics of tetracycline action. X1 cells were grown in 100-mm dishes to -80% confluency in the absence or presence (0.1 ug/ml) of tetracycline. At time 0 cells were washed with phosphate-buffered saline and split into smaller culture dishes (1/20th of the initial cultures per 35-mm dish). Half of the cultures remained in tetracycline-free medium (U) and the other half was incubated in the presence of tetracycline (1 ,ug/ml; o). The X1 culture grown in tetracycline-containing medium was split in the same manner: one half was further incubated in the presence of tetracycline (e), whereas the other half was transferred to tetracycline-free medium (o). At the times indicated, aliquots were harvested and examined for luciferase activity. The slight increase in luciferase activity monitored at 4 hr in the culture containing tetracycline (0) is reproducible and reflects luciferase induction during the washing step. two clones analyzed (T12 and X1), a stepwise reduction ofthe tetracycline concentration in the medium gradually increased the luciferase activity. These results again demonstrate that, in the case of clone X1, tTA can regulate transcriptional activity, as monitored by luciferase activity, by over five orders of magnitude. Moreover, we find that at tetracycline concentrations sufficient for full inactivation of tTA (0.1 ,ug/ml), no change in growth behavior or morphology of HeLa cells occurs. Only at tetracycline concentrations well above 10 ,ug/ml were such changes observed upon prolonged incubation (data not shown).
Kinetics of Tetracycline Action. The time course of tetracycline action was analyzed in cultures grown in the absence or presence oftetracycline. At time 0 the antibiotic was added to the tetracycline-free cultures (final concentration, 1 ,ug/ ml), whereas the tetracycline-containing cultures were rinsed and incubated in fresh, antibiotic-free medium (Fig. 3b) . At various times cells were harvested and analyzed for luciferase activity. As shown in Fig. 3b , the depletion of tetracycline leads to a rapid induction of luciferase activity, reaching >20%o of the fully induced level within 12 hr. A similarly rapid reduction of luciferase activity was observed when tetracycline was added to the fully active tetracyclinefree system: within 8 hr, activity dropped to about 10% and reached <2% of its original value after 12 hr.
DISCUSSION
The fusion ofthe TnJO-derived E. coli tetR with the activation domain of VP16 from HSV has generated a transactivator exhibiting all of the properties required for the specific and stringent regulation of an individual gene in a mammalian cell. The transactivator tTA produced in HeLa cells binds specifically to tetO sequences in vitro. This association is prevented by tetracycline. When bound to tetOs placed upstream of minimal promoters, tTA efficiently activates transcription from such promoters in vivo in a tetracyclinedependent manner. The transactivator is produced in HeLa cells in amounts sufficiently high for strong activation of transcription though low enough to avoid any detectable squelching effects (31) .
The usefulness of heterologous regulatory systems as the one described here depends decisively on quantitative parameters such as the extent of inactivation and the efficiency of activation of gene expression as well as the kinetics of transition from one state to the other. For the tet system these parameters were measured in HeLa cell lines that constitutively express tTA and that also contain the luciferase gene stably integrated and under the control of tTA-dependent promoters. The clones characterized thus far express the luciferase gene to various extents. This is not surprising since differences in the integration sites and in the number of integrated transcription units would be expected. However, in all cases the expression of luciferase is sensitive to tetracycline! In some clones tetracycline has the most dramatic effect of reducing the luciferase activity from high levels over several orders of magnitude to background. This demonstrates that in HeLa cells the two promoters Phcmv*-1 and PhCMv*-2 have no measurable intrinsic activity. Their function strictly depends on tTA. The residual luciferase activity observed in some clones in the presence of tetracycline must therefore be due to position effects.
The tTA-dependent promoters can be kept in a partially activated state by low concentrations of tetracycline. As shown in Fig. 3a , varying the tetracycline concentration between 0 and 0.1 ,ug/ml allows adjustment of promoter activity within a range of several orders of magnitude. This may allow assessment also of quantitative parameters ofgene function in vivo.
The activation and inactivation of tTA by the antibiotic appears to be not only an efficient but also a rapid process. When cells from tetracycline-containing medium are shifted to tetracycline-free medium, significant luciferase activity is induced within 4 hr and >20% of the steady-state level is reached within 12 hr after the shift. Interestingly, even the cultures that were only exposed to tetracycline-free medium during the washing procedure before reincubation in tetracycline-containing medium show a small but reproducible increase in luciferase activity that is still detectable after 4 hr (Fig. 3b) .
When tetracycline is added to a culture of X1 cells, luciferase activity is reduced -10-fold within 8 hr and >50-fold within 12 hr. This decrease is remarkably fast ifone takes into account the half-life of luciferase of around 3 hr reported for mammalian cells (measured by cycloheximide inhibition; refs. 33 and 34) and indicates a rapid uptake of tetracycline by HeLa cells followed by a fast and efficient shutdown of transcription. Although the half-life of luciferase and its mRNA remains to be determined in our system, these conclusions are supported by observations in plant cells, where tetracycline inactivates tetR within <30 min (23) .
Taken together, these data show that tetracycline, unlike IPTG in a eukaryotic lacR/O-based system, is able to act fast in cultures of mammalian cells. The possibility of rapidly switching the activity of a tTA-dependent promoter not only is of interest in studying gene function itself but also should allow analysis of mRNA decay rates of individual genes under physiological conditions.
In clone X1 tetracycline reduces luciferase activity reproducibly by five orders of magnitude. This suggests that binding of tetracycline to tTA may lower the association constant between the transactivator and its operator to a much greater extent than that measured for tetR (21) and as described for IPTG in the lacR/O system, where the binding constant KRO is reduced only 1000-fold by the inducer (35) .
On the other hand, preliminary results obtained in transient experiments with minimal tk promoters fused to single, dimeric, and heptameric tetO sequences strongly suggest a synergistic effect of multiple tTA binding sites. The efficient inactivation of tTA by tetracycline is therefore most likely due to a large difference in the binding constants of tTA and tTA/tetracycline for the tetO and the nonlinear effect of tetracycline interfering with a cooperative process.
In conclusion, our data indicate that promoter-activating systems as described here are most promising for regulating individual genes in higher eukaryotic cells for several reasons. (i) For activators, in particular when acting through a cooperative mechanism, intracellular concentrations can be kept low, ensuring an efficient inactivation by the effector-in this case, tetracycline. By contrast, repressors in general compete directly with transcription factors and/or RNA polymerases for binding within a promoter region. In the absence of cooperativity, however, the window at which the repressor concentration is sufficiently high for tight repression but still low enough for efficient induction may be narrow and not easily adjustable in different systems. (ii) In an activating system as described here the synthesis of tTA can be driven by a tissue-specific promoter, whereas the tTA-dependent promoters are expected to function tissue independently, since they may require only general transcription factors in addition to tTA. By contrast, in a repressorbased system in which operators have to be placed within the context of a promoter sequence, an influence on promoter specificity cannot be excluded. (iii) The tet system offers specific advantages when compared to the intensely studied lac system. For example, tetR binds tetracycline much tighter (ka 109 M-1; ref. 21 of tetracycline function effectively. Moreover, a large number of tetracycline derivatives are known, of which some appear to have far superior properties as effectors than the compound used in this study. In this context, it is interesting to note that detailed information on the pharmacological properties of tetracycline, in particular pharmacokinetic parameters, is available, which will facilitate application of this system in transgenic animals.
